​

Crescent Biopharma (CBIO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CBIO Stock Forecast

Crescent Biopharma (CBIO) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $32.00, with a high of $35.00 and a low of $26.00. This represents a 257.94% increase from the last price of $8.94.

CBIO Stock Rating

Crescent Biopharma stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (69.23%), 4 Hold (30.77%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 4 9 Strong Sell Sell Hold Buy Strong Buy

CBIO Price Target Upside V Benchmarks

TypeNameUpside
StockCrescent Biopharma257.94%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts234
Avg Price Target$35.00$34.00$32.00
Last Closing Price$8.94$8.94$8.94
Upside/Downside291.50%280.31%257.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2618---9
Jan, 26-7---7
Dec, 25-7---7
Nov, 2516---7
Oct, 2516---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 28, 2026Piper Sandler$35.00$11.27210.56%291.50%
Jan 21, 2026Brad CaninoGuggenheim$35.00$13.98150.36%291.50%
Dec 04, 2025Stephen WilleyStifel Nicolaus$32.00$12.99146.34%257.94%
Aug 25, 2025Jefferies$26.00$14.7076.87%190.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 28, 2026Piper SandlerOverweightinitialise
Jan 21, 2026GuggenheimBuyinitialise
Aug 25, 2025JefferiesBuyinitialise
Jul 14, 2025WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported---$-13.45---
Avg Forecast$-2.65$-0.98$-0.16$-0.03$-7.88$-4.94$-2.99
High Forecast$-2.65$-0.98$-0.16$-0.03$-6.00$-3.31$-1.98
Low Forecast$-2.65$-0.98$-0.16$-0.03$-10.47$-8.00$-3.58
Surprise %---44733.33%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-------
Avg Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
High Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
Low Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
Surprise %-------

Net Income Forecast

$-85M $-68M $-51M $-34M $-17M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported---$-71.47K---
Avg Forecast$-83.60M$-30.91M$-5.93M$-30.69K$-8.42M$-5.78M$-2.84M
High Forecast$-83.60M$-30.91M$-5.05M$-30.69K$-6.14M$-3.39M$-2.03M
Low Forecast$-83.60M$-30.91M$-5.05M$-30.69K$-10.71M$-8.18M$-3.66M
Surprise %---132.89%---

CBIO Forecast FAQ

Is Crescent Biopharma stock a buy?

Crescent Biopharma stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Crescent Biopharma is a favorable investment for most analysts.

What is Crescent Biopharma's price target?

Crescent Biopharma's price target, set by 13 Wall Street analysts, averages $32 over the next 12 months. The price target range spans from $26 at the low end to $35 at the high end, suggesting a potential 257.94% change from the previous closing price of $8.94.

How does Crescent Biopharma stock forecast compare to its benchmarks?

Crescent Biopharma's stock forecast shows a 257.94% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Crescent Biopharma over the past three months?

  • February 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Crescent Biopharma’s EPS forecast?

Crescent Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-7.88, marking a -41.41% decrease from the reported $-13.45 in 2024. Estimates for the following years are $-4.94 in 2026, and $-2.99 in 2027.

What is Crescent Biopharma’s revenue forecast?

Crescent Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $65M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $39.95M, and $5.62M for 2027.

What is Crescent Biopharma’s net income forecast?

Crescent Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-8.424M, representing an 11686.92% increase from the reported $-71.468K in 2024. Projections indicate $-5.785M in 2026, and $-2.844M in 2027.